physics4me

It has been a difficult week for two COVID-19 vaccines. On 13 April, US regulators urged health-care providers to temporarily stop using a vaccine made by Johnson & Johnson (J&J) of New Brunswick, New Jersey, because of six suspected cases of unusual blood clotting among nearly seven million vaccine recipients. The move came after European regulators expressed concerns about a possible link between rare blood clots and the Oxford–AstraZeneca vaccine, developed in the United Kingdom by AstraZeneca in Cambridge and the University of Oxford …. Read more at www.nature.com